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Preamble
t is becoming more apparent each day that despite
a strong national commitment to excellence in
health care, the resources and personnel are finite.
It is therefore appropriate that the medical profession
examine the impact of developing technology and new
therapeutic modalities on the practice of cardiology.
Such analyses, carefully conducted, could potentially
have an impact on the cost of medical care without
diminishing the effectiveness of that care.
To this end, in 1980 the American College of Cardi-
ology and the American Heart Association established
the Task Force on Assessment of Diagnostic and Ther-
apeutic Cardiovascular Procedures with the following
charge:
The task force of the American College of Cardiology
and the American Heart Association shall develop
guidelines relating to the role of new therapeutic ap-
proaches and of specific noninvasive and invasive pro-
cedures in the diagnosis and management of cardiovas-
cular disease.
The task force shall address, when appropriate, the
contribution, uniqueness, sensitivity, specificity, indica-
tions, contraindications, and cost-effectiveness of such
diagnostic procedures and therapeutic modalities.
The task force shall emphasize the role and values of
the guidelines as an educational resource.
The task force shall include a chair and six members,
three representatives from the American Heart Associa-
tion and three representatives from the American College
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of Cardiology. The task force may select ad hoc members
as needed upon the approval of the presidents of both
organizations. Recommendations of the task force are
forwarded to the president of each organization.
The members of the task force are George A. Beller,
MD; Robert A. O'Rourke, MD; J. Ward Kennedy, MD;
Robert C. Schlant, MD; Sylvan Lee Weinberg, MD;
William L. Winters, Jr, MD; and Charles Fisch, MD,
chair.
This document was reviewed by the officers and other
responsible individuals of the two organizations and
received final approval in June 1993. It is being pub-
lished simultaneously in Circulation and the Journal of
the American College of Cardiology. The potential effect
of this document on the practice of cardiology and some
of its unavoidable shortcomings are clearly set out in the
introduction.
Charles Fisch, MD
Introduction
The American College of Cardiology/American
Heart Association Task Force on Assessment of Diag-
nostic and Therapeutic Cardiovascular Procedures was
formed to gather information and make recommenda-
tions about appropriate use of technology in the diag-
nosis and treatment of patients with cardiovascular
disease. Coronary angioplasty is one such important
technique. We are currently witnessing an extraordinary
expansion of the use of coronary angioplasty as an
alternative means of achieving myocardial revascular-
ization. An estimated 300 000 angioplasty procedures
were performed in the United States in 1990, a more
than tenfold increase over the past decade.1 Such
growth is attributable not only to demonstrated clinical
benefit but also to continuing technical advances that
have led to improved techniques and higher success
rates over time. There was some concomitant broaden-
ing of the indications for both coronary angiography
and angioplasty, which led the task force to promulgate
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guidelines for coronary angiography in 19872 and guide-
lines for percutaneous transluminal coronary angio-
plasty (PTCA) in 1988.3 In view of the continuing
advances and expanding role of interventional cardiol-
ogy in clinical practice today, it was recommended that
this committee review current indications and proce-
dures governing the performance of angioplasty in the
United States and determine whether any alterations in
the previously published guidelines are warranted. Such
a review was anticipated and recommended in the
original committee report.3 This document presents the
summary opinion of the reconvened committee with its
newly constituted membership.
These recommendations were shaped over the course
of 9 months' deliberation and reflect much thoughtful
discussion and broad consultation, as well as a detailed
review of the world literature. The committee pro-
ceeded on the premise that angioplasty is an effective
means of achieving myocardial revascularization and its
appropriate use is to be broadly encouraged. At the
same time, the committee is mindful of the many forces
that can affect the performance of any specific proce-
dure and recognizes the potential for a variety of
inappropriate and expedient considerations to influence
the performance of angioplasty in this country. Accord-
ingly, the committee offers these recommendations with
a heightened awareness of the need for the cardiology
community at large, and institutional programs specifi-
cally, to police themselves in the use of coronary
angioplasty.
The technique of angioplasty is in evolution and the
long-term results are not yet fully elucidated; therefore,
even these revised recommendations are likely to
change over subsequent years. Because multiple vari-
ables must be weighed in selecting balloon angioplasty
treatment this report is not intended to provide strict
indications or contraindications for the procedure. Rel-
evant considerations include occupational needs, the
family setting, associated illnesses, and lifestyle prefer-
ences. Rather, the report is intended to provide a
statement of general consensus that may be helpful to
the practitioner as well as to health care administrators
and other professionals interested in the delivery of
medical care. The American College of Cardiology and
the American Heart Association recognize that the
ultimate judgment regarding the appropriateness of any
specific procedure is the responsibility of the physician
caring for the patient. The guidelines should not be
considered all-inclusive or exclusive of other methods
that may be available for the care of the individual
patient. The committee will not offer detailed recom-
mendations about the specific resources required to
perform coronary angioplasty or to train those perform-
ing the procedure. It is essential that physicians per-
forming angioplasty and related procedures are ade-
quately trained, that facilities and equipment used are
capable of obtaining the necessary radiographic infor-
mation, and that the safety record of the laboratory is
acceptable.
This report includes some general considerations that
provide a brief review of the growth and development of
the procedure, identification of contraindications to its
use, and a statement acknowledging general risks asso-
ciated with angioplasty. A brief discussion of consider-
tion of those factors currently recognized as influencing
the outcome, the requirement for surgical backup,
performance of angioplasty at the time of initial cathe-
terization, management of the patient after angioplasty,
the problems of restenosis and incomplete revascular-
ization, the need for periodic institutional credentialing,
and institutional mortality and morbidity review. Lastly,
specific guidelines for the application of coronary an-
gioplasty are presented; these were developed accord-
ing to anatomic (single versus multivessel disease),
clinical (asymptomatic versus symptomatic patients),
and physiological (presence or absence of inducible
ischemia) considerations. The indications derived from
consensus for angioplasty are judged to be either Class
I, II, or III (defined in "Indications for Angioplasty"),
based primarily on multifactorial risk assessment
weighed against expected outcome, judgments of feasi-
bility, appropriateness to the clinical setting, and overall
efficacy viewed in the light of current knowledge and
technology.
General Considerations
Background
Symptomatic coronary artery disease is present in
more than 6 million people in the United States.
Despite the availability of effective medical therapy, a
significant proportion of patients are candidates for a
revascularization procedure because of unacceptable
symptoms or potentially life-threatening lesions. An
estimated 300 000 coronary artery bypass operations
and 300 000 coronary angioplasty procedures were per-
formed in 1990.1 Although coronary angioplasty is still
performed most often in patients with single-vessel
coronary disease, increasing numbers of patients with
multivessel disease and those who have undergone
surgical bypass are also being treated. Coronary bypass
surgery is used most often to treat multivessel coronary
disease, with a majority of patients receiving three or
more bypass grafts. Use of the internal mammary artery
as a conduit has risen dramatically in recent years, from
less than 4% of the total number of procedures (an
estimated 6000) in 1983 to more than 60% of all
operations in 1990.1 The leading indication for surgery
continues to be relief of angina, an approach supported
by findings of randomized trials that have shown that,
compared with medical therapy, surgical revasculariza-
tion significantly reduces symptoms and improves qual-
ity of life.4 At the same time there has been an
expansion of the patients for whom it is recognized that
bypass surgery improves survival.5-12 This improvement
in survival has been established in patients with left
main coronary disease,5 certain patients with three-
vessel disease,6-8 some patients with two-vessel disease
when the proximal anterior descending coronary artery
is involved,7'9 as well as in subsets of patients with severe
symptoms10 or with a positive exercise test."1 Although
PTCA has been effective in alleviating angina in many
classes of patients, there have not yet been trials com-
paring angioplasty with medical therapy in the subsets
shown to have improved survival with surgery.
Immediate and Long-Term Results
Coronary angioplasty was first introduced by Andreas
ations unique to angioplasty follows with an enumera- Gruentzig in A7713 as an alternative form of revascu-
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larization. During the early years of its application
Gruentzig and others used angioplasty predominantly
to treat patients with discrete proximal noncalcified
subtotal occlusive lesions in a single coronary artery. In
subsequent years the technique has been used success-
fully in patients with multivessel disease, multiple sub-
total stenoses in the same vessel, certain complete
occlusions, partial occlusion of saphenous vein or inter-
nal mammary artery grafts, or recent total thrombotic
occlusions associated with acute myocardial infarction.
By 1980 Gruentzig had performed the procedure on
169 symptomatic patients, 40% ofwhom had multivessel
disease. The 10-year follow-up of those patients showed
persistent long-term benefit, with 89.5% of the patients
surviving and 75% remaining asymptomatic. Ten-year
survival in patients with single-vessel disease (95%)
exceeded that in patients with multivessel disease
(81%). Repeat angioplasty was required by 31% and
coronary bypass surgery by 31%.14 Five-year survival in
patients treated at Emory University in 1981, most of
whom had single-vessel disease, was 97%15 and at 10
years was 92%. The National Heart, Lung, and Blood
Institute established a PTCA registry in 1979 to help
evaluate the technique. Through 1982 a total of 3079
patients were entered into the voluntary registry, and
numerous analyses from this data bank have substanti-
ated the effectiveness and safety of angioplasty.16 Be-
cause technical advances resulted in improved success
rates and expanded application, a new registry was
opened by the NHLBI in 1985 to evaluate more recent
trends in angioplasty. Sixteen centers agreed to volun-
tarily collect data on an additional 2500 patients. The
primary clinical success rate increased from 61% in the
initial cohort to 78%.17 Despite a change in complexity,
with half of the cases in the second registry having
multivessel disease, the rate of nonfatal myocardial
infarction decreased from 4.9% to 4.3% and that of
emergency coronary artery surgery from 5.8% to 3.4%;
the mortality rate remained unchanged (1.2% and
1.0%). Five-year follow-up of the data from the second
registry indicates an overall survival rate of 90%.18
Investigators in a recently completed trial, Angio-
plasty Compared to Medical Therapy,19 compared an-
gioplasty with medical therapy in patients with single-
vessel disease. Although improved symptoms and a
modest increase in exercise performance were docu-
mented among the patients randomly assigned to
PTCA, there was no demonstrable effect on survival, a
feature also similar to surgical trials in patients with
single-vessel disease. This study is also noteworthy for
the observation that nearly 50% of the patients ran-
domly assigned to medical therapy became angina-free
during the 6-month period of observation.
In recent years, angioplasty in multivessel disease has
been associated with a mortality risk of approximately
1% to 2%,20-23 although it is recognized that the proce-
dure can have a higher risk in patients with more severe
disease. In the NHLBI registry, double-vessel disease
angioplasty was associated with a 0.9% in-hospital
mortality rate, while triple-vessel disease was associated
with a 2.8% mortality rate. The 5-year survival for
patients with single-vessel disease was 93.2%, for those
with double-vessel disease, 88.8%, and for those with
triple-vessel disease, 86%.18 In one report from a single
institution, involving 700 patients with multivessel dis-
ease (53% having double-vessel disease and 47% having
triple-vessel disease), the 5-year overall survival rate
was 88%. Event-free survival, defined as freedom from
death, Q-wave infarction, and coronary bypass surgery,
was 74%.23
Influence ofNew Devices
Two aspects of balloon angioplasty have motivated
cardiologists to seek alternative methods of improving
flow through obstructed arteries: the acute complica-
tions resulting from the angioplasty procedure itself and
the occurrence of late restenosis following the proce-
dure. Although atherectomy, laser angioplasty, and
stenting have improved initial results in certain ana-
tomic situations, the overall rates of acute complication
and restenosis with use of these devices have not
differed from those with balloon angioplasty.24,25 Al-
though in certain situations an operator may use an
approved new interventional device, it is to be noted
that these devices have been approved only for specific
indications that are more restrictive than those for
balloon angioplasty. These guidelines are based princi-
pally on experience with balloon angioplasty, and
throughout this document the term "angioplasty" will
be used to describe the procedure of endovascular
enlargement of the coronary lumen by a balloon or
other device.
Comparison With Bypass Surgery
Coronary angioplasty and coronary bypass grafting
are both intended to improve myocardial blood flow.
Both are palliative rather than curative and should be
seen as complementary rather than competitive proce-
dures. Both are associated with potential risks, includ-
ing stroke, myocardial injury, and death.
The major advantage of coronary angioplasty is its
relative ease of use, avoiding general anesthesia, thora-
cotomy, extracorporeal circulation, mechanical ventila-
tion, and prolonged convalescence. Repeat angioplasty
can be performed more easily than repeat bypass sur-
gery and revascularization can be achieved more quickly
in emergency situations. The disadvantages of angio-
plasty are high early restenosis rates and the inability to
relieve many stenoses because of the nature and extent
of the coronary lesion.
Coronary bypass surgery has the advantages of
greater durability (graft patency rates exceeding 90% at
10 years with arterial conduits) and more complete
revascularization irrespective of the morphology of the
obstructing atherosclerotic lesion.
Generally speaking, the greater the extent of coro-
nary atherosclerosis and its diffuseness through the
vessel wall, the more compelling the choice of coronary
artery bypass surgery, particularly if left ventricular
function is depressed. Patients with lesser extent of
disease and localized lesions are good candidates for
endovascular approaches. The use of either technique
assumes the presence of clinical indications such as
failure of medical treatment to control symptoms or a
potential survival benefit.
The use of the two technologies in terms of patient
selection and comparisons of outcome await the comple-
tion of several ongoing randomized clinical trials26 (the
Bypass Angioplasty Revascularization Investigation, the
Coronary Angioplasty Versus Bypass Revascularization
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Investigation, the Emory Angioplasty Surgery Trial, the
German Angioplasty Bypass Investigation, and Random-
ized Intervention Treatment ofAngina27) in which the two
treatments are compared in patients eligible for both
techniques. Changing technology, institutional and oper-
ator experience, and patient preference will continue to
influence choice of treatment.
The increasing use of angioplasty in suitable pa-
tients has materially affected the indications for the
coronary bypass operation. This has resulted in a
change in the case mix of patients undergoing bypass
surgery in recent years: they are generally older, have
diffuse, extensive coronary disease, often with im-
paired left ventricular function, and are higher-risk
patients than formerly.28 29 There is also a recognized
paucity of proper risk-adjusted comparisons between
coronary artery bypass surgery, PTCA, and medical
treatment. Based on data available in 1989, Wong et
a130 constructed a decision analytic model that ad-
dresses the question of when myocardial revascular-
ization is indicated for chronic stable angina. The
model considers angioplasty in addition to bypass
surgery and medical therapy and supports the recom-
mendation that revascularization is not indicated un-
less severe symptoms, other markers of substantial
ischemia, or severe multivessel disease are present.
The analysis also suggests that angioplasty may be
preferable to bypass surgery in patients with one- and
two-vessel disease. In a recent nonrandomized study
of consecutive patients treated with PTCA or coronary
artery bypass graft surgery (CABG) for multivessel
disease and left ventricular dysfunction, in-hospital
mortality rates were comparable (5% for CABG and
3% for PTCA).31 Although stroke was more common
in CABG patients (7% compared with 0%, P=.01),
there was a trend toward improved 5-year survival for
patients who had undergone bypass grafting compared
with those who had undergone PTCA (75% and 67%,
P=.09). Age and incomplete revascularization, but not
method of revascularization, were found upon multi-
variate analysis to correlate with late mortality. For a
more detailed comparison of CABG with PTCA, the
reader is referred to the ACC/AHA guidelines and
indications for coronary artery bypass surgery.12
Contraindications to Angioplasty
In general, the contraindications to angioplasty
include all of the relative contraindications enumer-
ated for the performance of coronary angiography as
outlined in the guidelines of an earlier ACC/AHA
report.2 Before undergoing angioplasty, it is impera-
tive that the patient clearly understand the procedure,
its potential complications, and the alternatives of
medical therapy or bypass surgery and have a truly
informed understanding of the risk-benefit ratio. The
importance of a relative contraindication to angio-
plasty will vary with the symptomatic state as well as
the general medical condition of the individual pa-
tient. Certain risks may be appropriate in severely
symptomatic individuals who, for example, are not
candidates for bypass surgery, whereas these risks
would be inadvisable for an asymptomatic or mildly
symptomatic individual. The currently accepted con-
traindications to the performance of elective coronary
angioplasty are the following.
1. Absolute contraindications
a. There is no significant obstructing lesion.*
b. There is a significant obstruction (>50%) in the
left main coronary artery and this main segment is not
protected by at least one nonobstructed bypass graft to
the left anterior descending or left circumflex artery.
c. There is no formal cardiac surgical program within
the institution.
2. Relative contraindications
a. A coagulopathy is present: conditions associated
with bleeding abnormalities or hypercoagulable states
may be associated, respectively, with unacceptable risks
of serious bleeding or thrombotic occlusion of a recently
dilated vessel.
b. The patient has diffusely diseased saphenous vein
grafts without a focal dilatable lesion.
c. The patient has diffusely diseased native coronary
arteries with distal vessels suitable for bypass grafting.
d. The vessel in question is the sole remaining circu-
lation to the myocardium.
e. The patient has chronic total occlusions with
clinical and anatomic features that result in a very low
anticipated success rate of dilation.
f. The lesion under consideration is a borderline
stenotic lesion (usually <50% stenosis).
g. The procedure is proposed for a non-infarct-
related artery in patients with multivessel disease who
are undergoing direct angioplasty for acute myocardial
infarction.
In addition to these generally accepted relative con-
traindications, there are other risks that cause clinicians
to have considerable reservations about the risk-benefit
ratio of angioplasty. These risks include those of abrupt
vessel closure, those associated with emergency bypass
surgery compared with elective surgery, as well as those
of restenosis. These risks are viewed as being on a
continuum, and their aggregate weight should ulti-
mately determine whether a specific procedure should
or should not be undertaken.
Patients with chronic renal failure may have in-
creased morbidity following coronary angioplasty due
to contrast-induced increased renal failure and subse-
quent prolonged hospitalization. Although coronary
angioplasty can be performed successfully in patients on
dialysis, the restenosis rate has been high (81% in one
report) and the long-term outcome has been unfavor-
able.32 Whether the long-term results of patients under-
going renal transplantation are better if coronary angio-
plasty is performed before or after the procedure is
unresolved.
Risks Associated With Angioplasty
Because coronary angioplasty requires visualization
of the coronary anatomy as well as systemic arterial and
venous access, patients undergoing the procedure are at
risk for the same complications associated with diagnos-
tic cardiac catheterization.2
Despite major improvements in angioplasty equip-
ment and operator skill, abrupt vessel closure remains
the major cause of morbidity and mortality, occurring in
3% to 8% of procedures, depending on the definition
*For the purpose of this report, a significant stenosis is defined
as one that results in a 5O5% reduction in coronary diameter as
determined by caliper method.
 by guest on M
arch 29, 2018
http://circ.ahajournals.org/
D
ow
nloaded from
 
AHA/ACC Task Force Guidelines for Percutaneous Transluminal Coronary Angioplasty 2991
used.33-39 Coronary artery dissection, with or without
thrombus, is the major cause of abrupt vessel closure.
Although coronary artery spasm appears occasionally to
be a contributing factor,40 in a number of studies
hypotension during or immediately after an angioplasty
procedure preceded abrupt vessel closure,36,41 with a
lack of adequate perfusion pressure presumably con-
tributing to the abrupt closure. Intra-aortic balloon
pumping42 and vasopressors may restore coronary ar-
tery perfusion pressure. Although successful resolution
of abrupt vessel closure has been accomplished with
percutaneous techniques in as many as two thirds of
patients,37 the condition is associated with a substantial
mortality rate (4% to 10%), and 20% to 30% of patients
require emergency bypass surgery, with 9% experienc-
ing Q-wave infarction.35,39,41
In the event of abrupt vessel closure, recrossing the
occluded segment and repeating balloon inflation, in-
serting a perfusion catheter, or using thrombolytic or
vasodilator agents can frequently reestablish coronary
artery patency and relieve ischemia.37'41'4344 Directional
coronary atherectomy has been successful in managing
selected cases with bulky plaque separation that pro-
duces vessel obstruction.45 The preliminary results of
intracoronary stents have shown promise in the man-
agement of the dissected coronary artery.46-50 The
subsequent management of patients with stents requires
a careful balance between adequate prolonged antico-
agulation to prevent thrombosis and avoidance of bleed-
ing complications. Prolonged maneuvers to reestablish
coronary patency are discouraged if they delay needed
surgical intervention and risk further myocardial dam-
age due to prolonged ischemia.
Peripheral vascular complications (particularly false
aneurysms and access site bleeding) may occur and are
usually associated with large guiding catheters, pro-
longed procedures, advanced age of the patient, and
periprocedural use of heparin or fibrinolytic agents.51
The large doses of contrast material required for com-
plex angioplasty procedures may also contribute to
morbidity by causing hemodynamic and renal dysfunc-
tion in some patients. Other infrequent complications
unique to coronary angioplasty include intracoronary
embolization of atherosclerotic or thrombotic material,
coronary perforation, laceration or rupture of a coro-
nary artery with subsequent hemopericardium, and
tamponade.
Certain high-risk patients who may have contraindi-
cations to coronary bypass surgery may be candidates
for coronary angioplasty. Hemodynamic support may be
necessary in these patients and multiple devices have
been used.52 The most experience is with intra-aortic
balloon pump counterpulsation; this technique has been
used with relatively low rates of morbidity and mortal-
ity.53 Emergency cardiopulmonary support has been
used in some centers but has the disadvantage of an
increased number of associated complications.54'55 In
addition, although the systemic circulation is supported
by this method, coronary perfusion is not provided
during hemodynamic collapse, and cardiopulmonary
support is not cardioprotective against global and re-
gional myocardial dysfunction.56 The indications for
cardiopulmonary support need further clarification, and
at present the technique should not be used to extend
the use of coronary angioplasty for higher-risk patients.
Need for Surgical Backup
Surgical backup, a service that was thought to be
essential during the developmental stages of angio-
plasty, is still provided in one form or another in most
cases of elective PTCA.
At present, 2% to 5% of patients undergoing PTCA
will sustain damage (dissection, intimal disruption, per-
foration, or embolization) to the coronary arteries,
requiring emergency surgical intervention. Emergency
coronary artery bypass grafting under these circum-
stances can be done effectively but with an operative
mortality higher than that encountered in comparable
patients managed with primary elective surgery.12'29'57
Many of these patients have one- or two-vessel disease
and would be uncomplicated surgical patients under
elective circumstances. The perioperative myocardial
infarction rate remains high, however, and the oppor-
tunity to use arterial conduits is reduced. The mortality
and myocardial infarction rates following emergency
surgery for failed PTCA increase with the extent of
coronary disease, the occurrence of cardiac arrest,
hemodynamic instability, and the need for cardiopul-
monary resuscitation, which is often required in these
circumstances. Also contributing to the increased mor-
tality and morbidity rates of emergency bypass surgery
for failed angioplasty are all the factors that prolong the
time to surgical reperfusion. These factors come into
play in patients who have had prior heart surgery, those
in whom conduit material is lacking, and especially in
those for whom the decision to proceed with emergency
surgical revascularization is delayed. Although no pro-
spective studies have been done to indicate which
patients experiencing failed angioplasty should have
emergency surgical revascularization, it is assumed that
most patients will benefit from an attempt at surgically
restoring myocardial blood flow under these circum-
stances. The indications for emergency CABG following
failed PTCA should follow the guidelines outlined in
the ACC/AHA task force report.12
Because of the variation in institutional practices of
cardiology and cardiac surgery, there is no standard
surgical backup for angioplasty. Surgical backup varies
from informal arrangements in which emergencies are
managed without prior planning or preparation to for-
mal standby in which an operating room is kept open
and an entire surgical team is immediately available.
However, there is concern that the universal require-
ment that angioplasty be done only in hospitals having
cardiac surgical capability is leading to the proliferation
in the United States of small-volume cardiac surgical
programs whose major role is to provide surgical backup
for angioplasty.
Data from centers in Canada and Europe, where
surgical programs are limited in number, suggest that
elective angioplasty can be performed in hospitals with-
out cardiac surgical capability with results comparable
to those of centers having this capability.58-60 It must be
acknowledged, however, that with more than 900 surgi-
cal/angioplasty units available in the United States, the
relative lack of surgical facilities in Canada and abroad
does not pertain here. This gives rise to the current
opinion in this country that to do elective angioplasty
without surgical backup exposes both the patient and
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physician to unnecessary risk and should not be done
routinely.61
Formal surgical standby that necessitates the expen-
diture of enormous resources to provide an operating
room, equipment, supplies, and highly trained person-
nel for a procedure that will be used less than 5% of the
time is both expensive and inefficient.62 For this reason,
surgical backup for angioplasty is increasingly provided
on a more informal basis. Better selection of patients
and lesions for angioplasty, better catheter systems,
improved technical competence, more stringent creden-
tialing, case-load requirements for those who perform
angioplasty, and various "bail-out" techniques have
made formal surgical standby less necessary than during
the developmental phase of coronary angioplasty.6364
The sine qua non for optimal patient care is good
communication among cardiologist, cardiac surgeon,
cardiac anesthesiologist, and support personnel in the
cardiac catheterization laboratory and operating room.
The current national standard of accepted medical
practice for coronary angioplasty requires that an expe-
rienced cardiovascular surgical team be available within
the institution* to perform emergency coronary bypass
surgery should the clinical need arise.3,12 Although
technical advances, operator experience, and alterna-
tive reperfusion strategies have somewhat lessened the
rate of emergency bypass surgery after failed elective
angioplasty, surgical backup has proved life-saving and
has effectively reduced subsequent morbidity such that
it is deemed mandatory by this committee for all elective
angioplasty procedures. After reviewing all the avail-
able evidence, being aware of the experience abroad
where on-site surgical backup is not a requirement and
mindful of the economic pressures to alter this standard
of practice, this subcommittee affirms its conviction that
such a policy is in the best interest of the patient.
For patients in whom angioplasty is clearly the most
appropriate method of therapy, formal surgical consul-
tation is not deemed necessary and will likely increase
costs and may result in longer hospitalizations. For
patients with high-risk features or in whom the extent of
the disease may indicate that bypass surgery is an
equally or more effective method of therapy, a surgical
consultation is advisable. This is especially true for
patients for whom a high rate of complications of either
angioplasty or bypass surgery may be anticipated.
The exact arrangement for surgical backup will vary
from one institution to another, depending on such obvi-
ous factors as the number of operating rooms available for
cardiac surgery and the number of surgeons, perfusionists,
nurses, and other personnel on hand. The essential re-
quirement is the capacity to provide surgery promptly
when angioplasty fails; otherwise, optimal patient care
may be seriously compromised.
The requirement for on-site surgical backup for pa-
tients undergoing emergency angioplasty for the man-
agement of acute myocardial infarction presents a spe-
cial problem. The committee recognizes that the
*"Within the institution" is generally intended to mean within
the same hospital. When two hospitals are physically connected
such that emergency transport by stretcher or gurney can be
achieved rapidly and effectively, the transport of patients between
the two hospitals for emergency cardiac surgical services would not
be considered off site.
requirement for on-site surgical backup greatly restricts
the use of this effective form of reperfusion therapy that
may provide survival benefit for certain high-risk pa-
tients suffering acute myocardial infarction. Both elec-
tive angioplasty and emergency procedures for unstable
ischemic syndromes and acute myocardial infarction
have generally been carried out in tertiary hospitals with
in-house cardiac surgical programs. Some cardiologists
have performed angioplasty procedures in patients with
acute infarction in hospitals that do not have surgical
programs because of the need for early reperfusion in
critically ill patients.6516 In some cases, transfer to a
tertiary facility would result in a longer period of
myocardial ischemia, which would reduce the benefits
resulting from reperfusion in these patients. It is clear
that very early reperfusion is of greater benefit than
later reperfusion, as demonstrated with thrombolytic
therapy initially in the GISSI-167 and ISIS-268 trials and
more recently in the MITI Study69 and the GUSTO
Trial.70 For this reason, the more widespread availabil-
ity of angioplasty for the management of acute infarc-
tion would potentially provide improved care for some
patients, particularly those with absolute contraindica-
tions to thrombolytic therapy. At the same time, it must
also be recognized that angioplasty carried out during
the early hours of acute myocardial infarction is fre-
quently difficult and requires even more skill and expe-
rience than routine angioplasty performed in stable
patients. However, the need for experienced operators
in this setting71 is not the only concern. It should be
emphasized that the experience of the laboratory tech-
nical staff and the availability of a broad range of
catheters, guidewires, and other devices are required for
optimal results in these acutely ill patients. Limiting
angioplasty in acute myocardial infarction to laborato-
ries with in-house surgical backup ensures that these
procedures are performed in laboratories that have
ongoing and regular experience with angioplasty. In
point of fact, surgical backup has become a surrogate
for experienced, well-equipped laboratories. This con-
sideration is far more important than the presence of
surgical backup, especially in light of the recognized
difference in the risk-benefit ratio of angioplasty per-
formed in the setting of an acute myocardial infarction.
Data from observational studies indicate that certain
high-risk patients with acute myocardial infarction, such
as those developing hypotension or congestive heart
failure or those in frank cardiogenic shock, benefit from
emergency angioplasty of the infarct-related artery.72,73
Such patients are considered to be in Class IIa in the
ACC/AHA task force guidelines for the early manage-
ment of patients with acute myocardial infarction.74
Thus, there may be patients at very high risk suffering
acute myocardial infarction, who may or may not be
suitable for thrombolytic therapy, in whom emergency
angioplasty without on-site surgical backup is accept-
able treatment if the ability to transfer the patient to an
established angioplasty center on a timely basis is not
possible or attendant with additional risk. When such an
approach is undertaken in the management of patients
with acute myocardial infarction, it is imperative that
both the operator and the supporting laboratory team
be highly experienced. In this setting the acute illness of
the patient and the nature of the procedure are ac-
knowledged to be beyond the capability of a purely
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TABLE 1. Recommendations for Clinical Competence In Percutaneous Transluminal Coronary Angiography: Minimum
Recommended Number of Cases Per Year
Bethesda Society for Cardiac ACC/ ACP/ACC/ ACC/AHA
Conference 1779 Anglography78 AHA3 AHA7 (1993)
Training
Total number of cases 125 125 125 125 125
Cases as primary operator 75 75 75 75 75
Practicing
Number of cases per year to
maintain competency ... 50 52 75 75
diagnostic catheterization laboratory. If experienced
angioplasty personnel can be quickly assembled in a
laboratory with full equipment for performing angio-
plasty, then the high-risk acute myocardial infarction
patient could benefit from urgent catheterization and
angioplasty at a site remote from a laboratory where the
procedure is performed routinely. Transfer to a center
with full support, including surgical capability, will often
be the more effective and efficient course of action. In
allowing exception for the need of on-site surgical
backup (angioplasty/surgical centers) in the manage-
ment of select, high-risk patients suffering acute myo-
cardial infarction, the committee feels compelled to
underscore its conviction that angioplasty/surgical cen-
ters constitute the best venue for all angioplasty
procedures.
Although many angioplasty procedures are scheduled
as clinically urgent or emergent (nonelective) therapy,
for example in patients with unstable angina, such
procedures should be undertaken only at institutions
with on-site surgical backup, ie, PTCA/surgical centers.
Because current medical practice dictates that unstable
angina should be managed initially by vigorous efforts to
stabilize the condition with medical therapy, there is
ample time to transfer such patients to institutions with
experienced cardiovascular surgeons on site. Indeed,
the view has long been held that patients with unstable
angina, especially those who are refractory to intense
medical therapy, should be transferred to institutions
with existing cardiac surgical programs for their initial
cardiac catheterization. In addition, recent data suggest
that immediate angioplasty in patients with unstable
angina may increase the risk of complications.75.7b
There are those who argue that patients who refuse
bypass surgery as a therapeutic option or those who are
considered nonsurgical candidates could reasonably un-
dergo angioplasty at institutions without on-site surgical
backup. The committee views such reasoning as spe-
cious and believes that truly informed judgments of this
kind are best made when such patients are in institu-
tions with experienced cardiovascular surgical teams, so
that all options can be adequately considered.
Need for Institutional Review
A rigorous mechanism for valid peer review must be
established and ongoing in each institution performing
coronary angioplasty because (1) angioplasty is an inter-
ventional procedure associated with known risks of
serious complications, including death, (2) it is a ther-
apeutic modality whose efficacy has a recognized asso-
ciation with operator skill and experience, and (3) in
certain instances, the procedure can be viewed as a
remunerative undertaking performed by the same phy-
sician who initiates and interprets the diagnostic studies
leading to the procedure itself.
Although institutional review can take many forms
and will vary according to such factors as the size of
institutions and departments, the number of staff, and
the volume of procedures, there are basic requirements
for a meaningful review. At a minimum, there must be
the opportunity for physicians, including those who do
not perform PTCAs but are knowledgeable about the
procedure, to review the overall results of the program
on a regular basis. Specific attention should be paid to
the general indications, the success and failure rates of
individual operators, the number of procedures per-
formed per operator, their rates of complications (in-
cluding emergency surgical procedures), and mortality
rates. The review process should examine and document
the quality and accuracy of cinearteriographic studies
and the appropriateness of indications, and it should
include discussion of contraindications. An active data-
base for quality assessment issues should be established.
The committee also identifies a critical need for the
institutional review process to ascertain that individual
operators meet national credentialing standards as pro-
mulgated by the ACP/ACC/AHA Task Force on Clin-
ical Privileges in Cardiology in its statement on clinical
competence in PTCA77 (Table 1). Documentation of
training in a structured fellowship program during
which a minimum of 125 coronary angioplasty proce-
dures, including 75 performed with the trainee as the
primary operator, is required to ascertain competence
in the procedure.77-79 A major concern is the reality that
a majority of operators fail to meet the requirements for
maintenance of competence, which is a minimum of 75
PTCA procedures performed per year as the primary
operator.3,77 While acknowledging that minimums do
not guarantee competence, the committee strongly en-
dorses the recommendations of the ACP/ACC/AHA
Task Force on Clinical Privileges in Cardiology and
believes the proliferation of small-volume operators
should be curtailed by appropriate institutional review.
To this end, the committee recommends that angio-
plasty operators who fail to meet these requirements
be required to discontinue the performance of the
procedure.
Maintenance of competence is important not only for
physicians performing PTCA but also for the institution
offering this service. A significant number of cases per
institution- at least 200 PTCA procedures annually- is
essential for the maintenance of quality and safe care.8"
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Exceptions to this minimum must be based on docu-
mentation of high-quality performance of appropriate
procedures within the institution.77
Institutions with medical or surgical groups, or both,
that cannot adequately meet the obligation of appropri-
ate institutional review should undertake regional re-
view with cooperating institutions or terminate their
program in angioplasty.
Specific Considerations
Successful Angioplasty and Its Determinants
A successful angioplasty procedure is defined as one
in which a .20% change in luminal diameter is
achieved, with the final-diameter stenosis <50% and
without the occurrence of death, acute myocardial
infarction, or the need for emergency bypass operation
during hospitalization. While this is the technically
accepted definition and the one used for the NHLBI
registry, it is conventional practice to reduce most
lesions to a final-diameter stenosis of <30%. Athero-
sclerotic coronary stenoses are considered significant if
they have the potential to impair coronary blood flow
under physiological circumstances. The visual assess-
ment of coronary narrowing on cineangiograms is asso-
ciated with substantial interobserver and intraobserver
variability. Although independent quantitative angio-
graphic techniques have become the gold standard for
evaluating coronary obstructions, determination of cor-
onary narrowing by caliper techniques is a readily
available technique that correlates closely with com-
puter quantitative methods for assessing percent steno-
SiS.81 For the purpose of this report, a significant steno-
sis is defined as one that results in a 50% reduction in
coronary diameter as determined by caliper method or
other quantitative angiographic technique.
After a decade of experience, it is now reasonable to
expect of any angioplasty program an overall initial
success rate of .90% for single lesion dilations. In
addition to operator experience, procedural success
relates to certain patient characteristics and, very im-
portantly, to angiographic characteristics of the lesion
or lesions to be dilated.
Patient-related factors influencing a successful dila-
tion are primarily younger age and male gender, but
clinical variables such as diabetes, prior myocardial
infarction, prior bypass surgery, and impairment of left
ventricular function are associated with procedural
morbidity and mortality.
Angiographic patterns outlining the morphological
characteristics of vessels and defining lesion-specific
characteristics have now been identified that may influ-
ence the likelihood of a successful dilation. Recognizing
the uniquely technical aspects of angioplasty and in an
attempt to risk-stratify any given procedure, the com-
mittee proposes that patients be stratified into low- and
increased-risk categories based on clinical and angio-
graphic variables. These variables may serve as a guide
for estimating the likelihood of a successful procedure
and, more importantly, the likelihood for abrupt coro-
nary occlusion or cardiovascular collapse should PTCA
fail.
Low-risk profile. Features associated with relatively
low risk for the angioplasty procedure are age <70
TABLE 2. Characteristics of Type A, B, and C Lesions
Lesion-Specific Characteristics
Type A lesions (minimally complex)
Discrete (length <10 mm)
Concentric
Readily accessible
Nonangulated segment (<450)
Smooth contour
Little or no calcification
Less than totally occlusive
Not ostial in location
No major side branch involvement
Absence of thrombus
Type B lesions (moderately complex)*
Tubular (length 10 to 20 mm)
Eccentric
Moderate tortuosity of proximal segment
Moderately angulated segment (>450, <900)
Irregular contour
Moderate or heavy calcification
Total occlusions <3 mo old
Ostial in location
Bifurcation lesions requiring double guide wires
Some thrombus present
Type C lesions (severely complex)
Diffuse (length >2 cm)
Excessive tortuosity of proximal segment
Extremely angulated segments >900
Total occlusions >3 mo old and/or bridging collaterals
Inability to protect major side branches
Degenerated vein grafts with friable lesions
*Although the risk of abrupt vessel closure may be moderately
high with Type B lesions, the likelihood of a major complication
may be low in certain instances such as in the dilation of total
occlusions <3 mo old or when abundant collateral channels
supply the distal vessel.
onary artery disease, no history of congestive heart
failure, left ventricular ejection fraction >40%, stable
angina, and <90% type A coronary stenosis.3,34,39,82-85
Type A coronary stenoses are discrete (.10 mm in
length) and concentric, and have the characteristics of
ready accessibility; location in a nonangulated segment
(<450); smoothness of contour; little or no calcification;
and absence of total occlusion, ostial location, major
side branch involvement, or thrombus (Table 2).
Increased-risk profile. Features associated with in-
creased risk for PTCA include advanced age, female
gender, multivessel and multilesion PTCA, diabetes
mellitus, history of congestive heart failure, degree of
left ventricular dysfunction, left main equivalent coro-
nary disease, inadequate antiplatelet therapy, unstable
angina pectoris, PTCA immediately following thrombo-
lytic therapy, and PTCA at the time of initial catheter-years, male gender, single-vessel and single-lesion cor-
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TABLE 3. Factors Predictive of Abrupt Vessel Closure
Preprocedure
Clinical factors
Female gender
Unstable angina
Insulin-dependent diabetes mellitus
Inadequate antiplatelet therapy
Angiographic factors
Intracoronary thrombus
>90% stenosis
Stenosis length 2 or more luminal diameters
Stenosis at branch point
Stenosis on bend (>450)
Right coronary artery stenosis
Postprocedure
Intimal dissection >10 mm
Residual stenosis >50%
Transient in-lab closure
Residual transstenotic gradient >20 mm Hg
ization for unstable angina pectoris.82-91 Lesion-specific
variables include stenoses .90% in severity, stenosis
bend angulation >450, excessive proximal vessel tortu-
osity, intraluminal thrombus, and type B or C charac-
teristics as enumerated in Table 2. Although many
experienced operators, using both conventional and
newer technologies, have success rates of .90% for
PTCA in lesions with type B or C characteristics,92-95 an
important note of caution has been sounded regarding
the interpretation and implications of such data, partic-
ularly as applied to the evaluation of newer technolo-
gies.93 Chronic total occlusions are the most significant
predictor of procedural failure but usually do not pose a
high risk to the patient.
Abrupt vessel closure. Although the correlates of pro-
cedural complications noted above may serve to stratify
groups of patients according to anticipated risk, they
generally have a low positive and negative predictive
value. Abrupt vessel closure during PTCA will occur in
3% to 8% of procedures and is largely unforesee-
able.33-39,41,96 Multivariate analyses have identified
branch vessel location, lesion length >10 mm, right
coronary artery stenosis, and coronary thrombus score
as independent preprocedural predictors of abrupt ves-
sel closure.97 Thrombus scores are determined by add-
ing up the number of angiographic features (haziness,
contrast stain, filling defect) that suggest the presence of
thrombus. Clinical and angiographic variables associ-
ated with abrupt coronary artery occlusion are summa-
rized in Table 3. Recent data have suggested that the
presence of thrombus is the most significant factor
associated with untoward events during PTCA.84,92
Cardiovascular collapse. Certain variables may be
useful in prospectively identifying patients at risk for
cardiovascular collapse if abrupt vessel closure compli-
cates PTCA.838496 A composite four-variable scoring
system, prospectively validated to be both sensitive and
specific in predicting cardiovascular collapse if PTCA
fails, includes (1) percentage of myocardium at risk, (2)
pre-PTCA percent diameter stenosis, (3) multivessel
coronary artery disease, and (4) diffuse disease in the
dilated segment.96 This index proved highly sensitive
and specific when prospectively compared with previ-
ously described risk factors such as >50% viable myo-
cardium at risk and left ventricular ejection fraction of
<25%. Similarly, a myocardial jeopardy score has been
devised to help determine the degree of viable myocar-
dium at risk for ischemic dysfunction.9899 This score
divides the coronary tree into six segments and assigns
two points to coronary segments subtended by stenoses
of .75% severity. Added weight is given to the left
anterior descending coronary distribution, which com-
prises three segments (Figure). Patients with higher
preprocedural jeopardy scores have a greater likelihood
of cardiovascular collapse should abrupt vessel closure
occur.84
Risk of death. The clinical variables associated with
increased mortality are identified as advanced age, fe-
male gender, diabetes, prior myocardial infarction, mul-
tivessel disease, left main or equivalent coronary disease,
a large area of myocardium at risk, impairment of left
ventricular function, and collateral vessels supplying sig-
nificant areas of myocardium that originate distal to the
segment to be dilated.41,82-84100101 Recent data have
shown that the increased mortality among women under-
going angioplasty, compared with men, is associated with
older age, more clinical heart failure, and unstable
angina. Despite having more hypertension and diabetes,
the extent of coronary artery disease in women under-
going angioplasty is no greater than that among
men.102,103 Death is directly related to the occurrence of
coronary artery occlusion and is most frequently due to
left ventricular failure.84 Left ventricular failure was
independently correlated with the coronary artery jeop-
ardy score, female gender, and PTCA of a proximal right
coronary artery stenosis. Factors associated with death
following angioplasty are listed in Table 4.
These clinical variables can be assessed before the
performance of PTCA and should help to determine
procedural risk, particularly the risk of abrupt vessel
closure and cardiovascular collapse. Patients having a
higher-risk profile may be candidates for alternative
therapies, particularly coronary bypass surgery, or for
more formalized surgical standby or periprocedural
hemodynamic support.
Angioplasty at the Time of Initial
Cardiac Catheterization
The selection of patients for angioplasty demands
careful review of the clinical and anatomic features of
each case. This is optimally done after diagnostic car-
diac catheterization and review of the cineangiograms.
This process, however, obviously subjects the patient to
a repeat invasive procedure with its inherent risk and
recognized morbidity, lengthens hospitalization, and
adds to the direct and indirect costs involved.
A staged approach to coronary angioplasty after
cardiac catheterization has certain advantages: it allows
more time to plan the dilation strategy, to have consul-
tation with colleagues, to have more extensive discus-
sion with the patient and family, and to review the
therapeutic options. However, in some patients who are
informed in anticipation of a combined procedure and
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Diagrammatic illustration of coro-
nary artery jeopardy score seg-
ments for patients with either
right coronary (panel A) or left
coronary (panel B) dominance.
Coronary segments subtended
by stenoses of .75% severity
are assigned two points. The oc-
currence of cardiogenic shock
after abrupt vessel closure is
more frequently observed with
jeopardy scores of .5.0 in men
or .3.5 in women. Diag or DIAG
indicates diagonal branch; LAD,
left anterior descending; LCx, left
circumflex; LM, left main coro-
nary artery; MARG or OM, obtuse
marginal branch; PDA, posterior
descending coronary artery; PL,
posterolateral branch; RCA, right
coronary artery; Sept or SEPT,
septal branch. Adapted from Ref-
erences 84 and 99 with
permission.
who have suitable coronary anatomy, performing com-
bined coronary angiography and angioplasty reduces
the hospital stay by 30%, reduces costs by 15%, and
reduces radiation exposure without compromising the
safety of the procedure.104,105
Combined angiography and PTCA is particularly
suitable for three subsets of patients: (1) patients with
unstable angina that cannot be stabilized who require
urgent PTCA, (2) patients with signs or symptoms
suggesting restenosis following PTCA within the previ-
ous 12 months, and (3) patients undergoing PTCA for
an acute myocardial infarction with planned PTCA of
only the infarct artery. In all instances pretreatment
with aspirin is very important.106-108
In some other elective cases, PTCA can also be
performed safely immediately after coronary angiogra-
TABLE 4. Factors Associated With Increased Mortality
For Angloplasty
Clinical Factors
Female gender
Age >65 years
Unstable angina
Congestive heart failure
Chronic renal failure
Anglographic Factors
Left main coronary disease
Three-vessel disease
Left ventricular ejection fraction <0.30
Risk index*
Myocardial jeopardy score
Proximal right coronary stenosis
Collaterals originate from dilated vessel
*See reference 96.
phy without additional complications if the lesions are
clearly identified at angiography with high-quality im-
age systems and the patient is well informed and
prepared before the procedure.109 In all cases, however,
any decision regarding PTCA should be delayed if there
is any question about the need for, the suitability of, or
the preference for PTCA as opposed to medical or
surgical treatment.
Postangioplasty Management
Immediately after coronary angioplasty, attention is
directed to monitoring for evidence of recurrent isch-
emia, to ensuring appropriate hemostasis at the site of
catheter insertion, and to detecting and preventing
contrast-induced renal injury. Specific protocols for
sheath removal, continuation of anticoagulation, and
administration of antiplatelet therapy will vary from
institution to institution and with the complexity of the
procedure. Special skilled nursing units have been de-
veloped in some institutions to facilitate post-PTCA
management. Most patients can be safely discharged
from the hospital within 24 to 48 hours after an uncom-
plicated angioplasty.
A small portion of patients in whom angioplasty was
judged angiographically successful will experience
symptoms of myocardial ischemia during the observa-
tion period after the procedure. If electrocardio-
graphic abnormalities suggesting ischemia are de-
tected, there is a substantial risk of abrupt vessel
closure, which has been associated with a compara-
tively high mortality rate.33-39 An individual judgment
must be made as to whether additional angioplasty,
emergency bypass surgery, or continued medical ther-
apy is appropriate. Accordingly, the equipment and
services required to perform repeat angiography and,
if necessary, repeat angioplasty or CABG need to be
available 24 hours per day in any institution that offers
an angioplasty program.
A B
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Patients must be instructed about appropriate risk-
factor modification before their discharge from the
hospital. Depending on the patient, advice should in-
clude hypertension control, diabetic management, ag-
gressive control of the serum lipids following American
Heart Association guidelines, abstinence from tobacco,
weight control, regular exercise, and timing of return to
full activities. Patients should be informed of the impor-
tance of contacting their physician if symptoms recur.
To date no pharmacologic therapy has been shown to
prevent restenosis.110
Follow-up studies to detect restenosis and recurrent
myocardial ischemia are helpful in the patient manage-
ment after PTCA. A treadmill test done within days or
a few weeks of angioplasty is reassuring if negative
(particularly if it was positive preangioplasty) and can
be useful in providing advice on exercise and work
capacity. A positive exercise test 3 to 6 months after
PTCA is suggestive of restenosis, particularly if angina
is present."1 Exercise or pharmacologic stress echocar-
diography and stress perfusion scintigraphy have also
been used for the detection of significant restenosis and,
in asymptomatic patients, may be somewhat more spe-
cific than exercise stress electrocardiography.1"2-"14
Some 12% to 20% of asymptomatic patients will have
significant angiographic restenosis 6 months after PTCA.
In many cases, this can be detected by noninvasive stress
tests.1"5,'6 However, if a patient has no angina, has a
negative stress ECG, or negative results on stress perfu-
sion scintigraphy, the probability of a significant restenosis
is approximately 5%.115,116 In the absence of symptoms, a
modest reversible defect on stress perfusion scintigraphy
may not justify repeat angioplasty. Coronary angiography
may be indicated in some patients without evidence of
myocardial ischemia because of special employment or
occupational requirements or other factors judged to be
important by their physician.
If significant clinical restenosis is identified at any
time after PTCA, indications for repeat PTCA should
follow the general indications as outlined in "Indica-
tions for Angioplasty." If restenosis has not occurred by
6 months after PTCA, it is unusual for it to develop
later; subsequent clinical evidence of myocardial isch-
emia is usually associated with progression of disease
elsewhere in the coronary tree.117
Restenosis
Although the initial outcome for coronary angio-
plasty procedures has improved over the past 15 years,
the incidence of coronary restenosis after dilation has
remained unchanged at 30% to 40% and is perhaps
higher in certain complex lesions.1"0,1'8,1'9 The rate of
restenosis in native arteries depends partly on its defi-
nition. Of the different restenosis criteria proposed, a
>50% diameter stenosis at follow-up angiography is the
most frequently used.120 Investigators using quantitative
angiographic techniques have proposed using the
change in minimal lumen diameter from that after
PTCA to that at follow-up, normalized for the reference
vessel diameter (relative loss).121-23 Ultimately it is the
minimal lumen diameter of the residual stenosis after
healing related to the vessel's normal size that is impor-
tant. A dichotomous variable such as >50% stenosis at
follow-up may work well in clinical practice, but it is to
be noted that all dilated arteries undergo some healing.
For this reason, the continuous variables of minimal
lumen diameter or percent diameter stenosis at fol-
low-up best describe restenosis in large patient popula-
tions. Accordingly, they should be used in clinical trials
aimed at altering the restenosis process.
The pathogenesis of the restenotic process subse-
quent to mechanical injury is incompletely understood
but appears multifactorial. The principal factors include
elastic recoil, organization of thrombus adherent to the
site of arterial injury, and growth factor stimulation of
smooth muscle proliferation.124-'26
The value of symptoms for detecting restenosis has
varied widely among studies, although on average, 60%
to 70% of patients with recurrent angina within 6
months of PTCA have restenosis and 10% to 20% of
those without recurrent symptoms have restenosis.1"0
Patient-related factors that appear to predispose the
patient to restenosis include male gender, continued
smoking after angioplasty, diabetes, elevated blood
insulin levels, absence of previous myocardial infarc-
tion, and unstable angina,1"9,126,127 although one recent
analysis has questioned the relationship of smoking to
restenosis.28 Angiographic factors related to restenosis
include angioplasty of the proximal left anterior de-
scending coronary, the presence of chronic total coro-
nary occlusion, stenoses at the origin of vessels, branch
vessel stenoses, long lesions, the presence of thrombus,
and stenoses involving the proximal and middle regions
of saphenous vein bypass grafts."10"'18,1'9"126 Data from
one recent report, however, suggest that, at least with
respect to the rate of restenosis observed in diverse
segments of the coronary tree, restenosis is an ubiqui-
tous phenomenon without predilection for a particular
site or segment.'23 Procedural variables related to reste-
nosis include postangioplasty residual stenosis of >30%
and pressure gradient of >15 mm Hg. Extensive coro-
nary dissection appears to be associated with a high rate
of restenosis."10,118-'20
Factors that have not been correlated with an in-
creased incidence of restenosis include age, functional
class, history of previous myocardial infarction, hyper-
tension, serum cholesterol, presence of calcification at
the site of dilation, morphological features of the lesion,
inflation pressure, and medications taken at time of
discharge.
Patients who develop clinical or angiographic evi-
dence of restenosis in native coronary arteries usually
undergo a second dilation procedure. For repeat angio-
plasty, the primary success rate appears higher than for
the initial procedure with a relatively low incidence of
myocardial infarction or need for emergency coronary
artery bypass surgery. The rate of recurrent restenosis,
however, is somewhat higher than the rate of restenosis
after the initial procedure.'29
Incomplete Revascularization
As coronary angioplasty is being used in more com-
plex clinical and pathoanatomic situations, the concern
arises that patients are being subjected to incomplete
revascularization or less-than-optimal correction of
their pathophysiological state. The surgical experience
is convincing that complete revascularization leads to
superior results in terms of relief of angina, less myo-
cardial ischemia, better hemodynamic performance on
postoperative stress testing, and freedom from subse-
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quent coronary events including reoperation, myocar-
dial infarction, and death.130
Incomplete or partial revascularization is often a
preplanned therapeutic strategy in patients undergoing
angioplasty because of morphological factors preclud-
ing successful dilation of all lesions (eg, chronic total
occlusions, mild lesions).92,131 Although early graft clo-
sure after bypass surgery also converts complete revas-
cularization to partial revascularization, this phenome-
non is less common than restenosis after angioplasty.
Some studies have suggested that incomplete revascu-
larization in patients undergoing angioplasty may also
unfavorably influence long-term survival.23'31'132
Partial revascularization after coronary angioplasty is
an inherent limitation of the procedure and can be
expected to occur more frequently in patients undergo-
ing multivessel angioplasty. Frequently, especially in
elderly patients, only one targeted lesion thought to be
responsible for the patient's symptoms is dilated to
reduce the risk of the procedure. Nonetheless, many
patients experience relief of symptoms despite partial
revascularization when one or more significant lesions
supplying large areas of viable myocardium have been
dilated.133-137 In addition, multiple successive interven-
tions are feasible, unstable patients may be stabilized,
and surgical revascularization may be deferred. The
cost, in terms of clinical outcome, associated with such
a strategy in patients with multivessel disease compared
with an initial strategy of surgical revascularization
awaits the outcome of ongoing clinical trials.
Those performing CABG and PTCA use different
strategies; surgeons bypass all lesions possible, PTCA
operators dilate the most significant. Incomplete revas-
cularization after CABG is primarily related to ungraft-
able severe distal disease or prior infarction and is thus
correlated with a higher late mortality. Incomplete
revascularization after PTCA is more likely the result of
a strategy not to dilate milder stenoses, inaccessible
lesions, or chronic total occlusions, and thus does not
correlate closely with late mortality.138
Indications for Angioplasty
The approach to every angioplasty procedure re-
quires careful consideration of the likelihood of a
successful procedure* compared with the likelihood of
failure and the risk of complications (abrupt vessel
closure, morbidity, mortality, or restenosis). In priori-
tizing indications for angioplasty, the committee was
greatly influenced by the items discussed in "Specific
Considerations": (1) factors favoring a successful dila-
tion; (2) factors associated with and consequences of
abrupt vessel closure; (3) restenosis; (4) incomplete
revascularization; and (5) the consequences of failure of
the procedure.
Both clinical judgment and statistical estimates per-
mit appropriate weighting and integration of impor-
tant variables to formulate likelihood estimates (high,
moderate, or low) of the success of any given proce-
dure according to the likelihood of a successful dila-
tion (see Tables 2 and 4); the likelihood of abrupt
vessel closure, with subsequent morbidity and mortal-
ity (Table 3); the likelihood of restenosis; and the
long-term prognosis.
Although operator experience and individual patient
characteristics are important factors relating to out-
come, both procedural success and abrupt vessel closure
are in large part determined by specific patient charac-
teristics and lesion morphology.139,140 It must be recog-
nized that this aspect of cardiovascular care is undergo-
ing considerable growth and development and that
frequent updates may be required as new insights are
gained. Currently, the following classifications are used
to indicate the degree of consensus of the committee
members and the reviewing bodies for specific applica-
tions of angioplasty:
Class I: Conditions for which there is general agree-
ment that coronary angioplasty is justified. A Class I
indication does not mean that coronary angioplasty is
the only acceptable therapy.
Class II: Conditions for which there is divergence of
opinion with respect to the justification for coronary
angioplasty in terms of value and appropriateness.
Class m: Conditions for which there is general agreement
that coronary angioplasty is not ordinarily indicated.
Single-Vessel Coronary Artery Disease
Asymptomatic or mildly symptomatic (functional Class
I) patients with or without medical therapy: symptoms are
defined in accordance with the Canadian Cardiovascular
Society classification (Appendix A)
Class I
This category applies to patients who have a signifi-
cant lesiont in a major epicardial artery that subtends a
large area of viable myocardium and who
1. show evidence of severe myocardial ischemia dur-
ing laboratory testing, ie, ischemia induced by low-level
exercise (Bruce Stage 1 or less or <4.0 METS, or heart
rate < 100 beats per minute) and manifested by
a. ischemic ST segment depression .1 mm in multi-
ple leads or lasting >3 minutes into recovery, or
b. systolic hypotension during exercise, or
c. evidence of a significant area of ischemia on
nuclear, echocardiographic, or radionuclide angio-
graphic stress testing or a moderate area of ischemia
with increased lung thallium 201 uptake, or
d. exercise-induced reduction in the ejection fraction
or wall motion abnormalities on radionuclide ventricu-
lographic studies, or both, or
2. have been resuscitated from cardiac arrest or from
sustained ventricular tachycardia in the absence of
acute myocardial infarction, or
3. who must undergo high-risk noncardiac surgery,
such as repair of an aortic aneurysm, iliofemoral bypass,
or carotid artery surgery, if angina is present or there is
objective evidence of ischemia as described above.
All of these patients should have a lesion or lesions
associated with a high likelihood of successful dilation,
and be at low risk for morbidity and mortality.
tFor the purpose of this report, a significant stenosis is defined
as one that results in a 250% reduction in coronary diameter as
determined by caliper method.
*A successful procedure is defined as one in which a 220%
change in luminal diameter is achieved with the final diameter
stenosis <50%, without the occurrence of death, acute myocardial
infarction, or bypass operation during hospitalization.
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Class II (mild or no symptoms, single-vessel coronary
disease)
This category applies to patients who have a signifi-
cant lesion in a major epicardial artery that subtends at
least a moderate-sized area of viable myocardium and
1. show objective evidence of myocardial ischemia*
during laboratory testing and
a. have at least a moderate likelihood of successful
dilation, and
b. have a low risk of abrupt vessel closure, and
c. are at low risk for morbidity and mortality.
Class III (mild or no symptoms, single-vessel coronary
disease)
This category applies to all other patients with single-
vessel disease and mild or no symptoms who do not
fulfill the preceding criteria for Class I or Class II. It
includes, for example, patients who
1. have only a small area of viable myocardium at risk,
or
2. do not manifest evidence of myocardial ischemia
during laboratory testing, or
3. have borderline lesions (50% to 60% diameter
reduction) and no inducible ischemia, or
4. are at moderate or high risk for morbidity and
mortality.
In some patients, circumstance of occupation or
employment may result in a Class II indication being
viewed as a Class I category. Such patients would
include those whose occupation involves the safety of
others (eg, airline pilots, bus drivers, truck drivers, and
air-traffic controllers) and those in certain occupations
that frequently require sudden vigorous activity (eg,
firefighters, police officers, and athletes). However,
Class III indications for asymptomatic or mildly symp-
tomatic individuals with single-vessel disease pertain to
a risk profile that precludes the patient's belonging in
Class I or Class II.
Symptomatic patients with angina pectoris (functional
Classes II to IV, unstable angina) with medical therapy
and single-vessel disease
Class I
This category applies to patients who have a signifi-
cant lesion in a major epicardial artery that subtends at
least a moderate-sized area of viable myocardium and
who
1. show evidence of myocardial ischemia while on
medical therapy (including ECG monitoring at rest), or
2. have angina pectoris that is inadequately respon-
sivet to medical treatment, or
3. are intolerant of medical therapy because of un-
controllable side effects.
All of these patients should have at least a moderate
likelihood of successful dilation and be at low or mod-
erate risk for morbidity and mortality.
*Evidence of myocardial ischemia during laboratory testing is
taken to mean exercise-induced ischemia (with or without exer-
cise-induced angina pectoris) manifested by 2 1 mm of ischemic
ST segment depression and/or one or more stress-induced
reversible nuclear perfusion defects and/or exercise-induced
reduction in the ejection fraction and/or wall motion abnormal-
ities on radionuclide ventriculographic or stress echocardio-
graphic studies.
fInadequately responsive" as used in this report means that
patient and physician agree that angina significantly interferes with
the patient's occupation or ability to perform usual activities.
Class II (symptomatic, single-vessel coronary disease)
This category applies to patients who have a signifi-
cant lesion in a major epicardial artery that subtends at
least a moderate-sized area of viable myocardium and
who
1. show evidence of myocardial ischemia during lab-
oratory testing and
a. have one or more complex (type B or C morphol-
ogy) lesions in the same vessel or its branches, or
b. are at moderate risk for morbidity, or
2. have disabling symptoms and a small area of viable
myocardium at risk, and
a. at least a moderate likelihood of successful dilation
and
b. are at low risk for morbidity and mortality, or
3. have at least moderately severe angina on medical
therapy with equivocal or nondiagnostic evidence of
myocardial ischemia on laboratory testing and who
prefer treatment with coronary angioplasty to medical
therapy, and
a. have at least a moderate likelihood of successful
dilation, and
b. are at low risk for morbidity and mortality.
Class Ill (symptomatic, single-vessel coronary disease)
This category applies to all other symptomatic pa-
tients with single-vessel disease who do not fulfill the
preceding criteria for Class I or Class II. It includes, for
example, patients who
1. have no or only a small area of viable myocardium
at risk in the absence of disabling symptoms, or
2. have clinical symptoms not likely to be indicative of
ischemia, or
3. have a very low likelihood of successful dilatation,
or
4. are at high risk for morbidity and mortality, or
5. have no symptoms or objective evidence of myo-
cardial ischemia during high-level stress testing (>12
METS).
Patients with single-vessel disease who have significant
symptoms constitute one of the largest groups of patients
undergoing angioplasty. However, the generally excellent
prognosis for patients with single-vessel disease should
be a paramount consideration before an interventional
procedure is undertaken in these patients. It is impera-
tive that there be some assurance that the significant
symptoms are indeed due to the coronary lesion pro-
posed for dilation. Although significant symptoms may
justify a lower tolerance for the risk of abrupt vessel
closure or subsequent restenosis, one cannot compro-
mise on the risk for significant mortality or morbidity. In
view of evidence that angina can diminish, or even
disappear, in many patients with occlusive coronary
disease, especially those with single-vessel disease, pa-
tients should be informed before angioplasty of the
possibility that their symptoms may improve spontane-
ously on medical treatment alone.
Multivessel Coronary Artery Disease
Asymptomatic or mildly symptomatic (functional Class
I) patients with or without medical therapy
Class I
This category applies to patients who have one sig-
nificant lesion in a major epicardial artery that could
result in nearly complete revascularization because the
additional lesion(s) subtends a small viable or nonviable
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area of myocardium. Additionally, patients in this cat-
egory must
1. have a large area of viable myocardium at risk, and
2. show evidence of severe myocardial ischemia while
on medical therapy during laboratory testing, or
3. have been resuscitated from cardiac arrest or from
sustained ventricular tachycardia in the absence of
acute myocardial infarction, or
4. be undergoing high-risk noncardiac surgery and
demonstrate objective evidence of myocardial ischemia.
All of these patients should have one or more lesions
that would have a high success rate, the successful
dilation of which would provide relief to all major
regions of ischemia, and be at low risk for morbidity and
mortality.
Class II (mild to no symptoms, multivessel coronary
disease)
This category applies to patients
1. who are similar to patients in Class I but who
a. have a moderate-sized area of viable myocardium at
risk, or
b. have objective evidence of myocardial ischemia
during laboratory testing, or
2. who have significant lesions in two or more major
epicardial arteries, each of which subtends at least a
moderate-sized area of viable myocardium, or
3. who have a subtotally occluded vessel requiring
angioplasty wherein the development of total occlusion
of the vessel would result in severe hemodynamic col-
lapse due to left ventricular dysfunction.
All of these patients should show evidence of myo-
cardial ischemia during laboratory testing, have lesions
with at least a moderate likelihood of successful dila-
tion, the successful dilation of which would provide
relief to all major regions of ischemia, and be at low or
moderate risk for morbidity and mortality.
Class III (mild to no symptoms, multivessel disease)
This category applies to all other patients with mul-
tivessel disease and mild or no symptoms who do not
fulfill the above criteria for Class I or Class II. It
includes, for example, patients who
1. have only a small area of viable myocardium at risk,
or
2. have chronic total occlusions in major epicardial
vessels subtending moderate or large areas of viable
myocardium, or
3. are at high risk for morbidity or mortality.
Symptomatic patients with angina pectoris (functional
Classes II to IV, unstable angina) with medical therapy
and multivessel disease
Class I
This category applies to patients who have significant
lesions in two or more major epicardial arteries both
subtending at least moderate-sized areas of viable myo-
cardium and who
1. show evidence of myocardial ischemia while on
medical therapy during laboratory testing, or
2. have unstable angina or angina pectoris that has
proved inadequately responsive to medical therapy, or
3. are intolerant of medical therapy because of un-
controllable side effects.
All of these patients should have lesion morphology
associated with a high rate of successful dilation, which
would provide relief of all major regions of ischemia,
and be at low risk for morbidity and mortality.
Class II (symptomatic, multivessel disease)
This category applies to patients who have significant
lesions in two or more major epicardial arteries that
subtend at least moderate-sized areas of viable myocar-
dium and who
1. are similar to patients in Class I but who are at
moderate risk for morbidity and mortality, or
2. have angina pectoris but do not necessarily have
objective evidence of myocardial ischemia during labo-
ratory testing.
All of these patients should have lesion morphology
associated with a high rate of successful dilation,
which would provide relief of all major regions of
ischemia, and be at moderate risk for morbidity and
mortality.
Patients in this category also are those who
3. have disabling angina that has proved inadequately
responsive to medical therapy and
a. are considered poor candidates for surgery because
of advanced physiologic age or coexisting medical dis-
orders, and
b. have lesions with at least a moderate likelihood of
successful dilation, and
c. are at moderate risk for morbidity and mortality, or
4. have a subtotally occluded vessel requiring angio-
plasty and the total occlusion of the vessel would result
in severe hemodynamic collapse due to left ventricular
dysfunction.
Class III (symptomatic, multivessel coronary disease)
This category applies to all other symptomatic pa-
tients with multivessel disease who do not fulfill the
preceding criteria in Class I or Class II. It includes, for
example, patients who
1. have only a small area of myocardium at risk in the
absence of disabling symptoms, or
2. have lesion morphology with a low likelihood of
successful dilation and subtending moderate or large
areas of viable myocardium, or
3. are at high risk for morbidity or mortality, or
both.
It is to be stressed that risk assessment is different in
patients with multivessel disease than in those with
single-vessel disease. In the former group there ideally
should be the opportunity for anatomically complete
revascularization, although adequate functional revas-
cularization can be achieved without necessarily being
anatomically complete. In every instance the goal is to
achieve relief of ischemia at a risk acceptable for the
procedure. In estimating this risk in multivessel dis-
ease it is imperative that each lesion be considered in
the context of all other lesions present. Some assess-
ment must then be made of the likely consequences
should any one of the attempted dilations fail and
result in abrupt vessel closure. For example, there is
an increased risk in dilating a left coronary artery
lesion if it jeopardizes the entire collateral blood
supply to a large area of viable myocardium in the
distribution of a totally occluded, nondilatable, domi-
nant right coronary artery.14' On occasion exceptions
to these guidelines may be made based on operatorjudgment, experience, and the patient's desires, par-
ticularly in some patients at higher risk for a proce-
dural complication.
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Direct Immediate Coronary Angioplasty for Evolving
Acute Myocardial Infarction
Class I
This category applies to the dilation of a significant
lesion in the infarct-related artery only in patients who
can be managed in the appropriate laboratory setting and
who
1. are within 0 to 6 hours of the onset of a myocardial
infarction (the procedure is used as an alternative to
thrombolytic therapy),
2. are within 6 to 12 hours of the onset of a myocardial
infarction but who have continued symptoms of ongoing
myocardial ischemia, or
3. are in cardiogenic shock with or without previous
thrombolytic therapy and within 12 hours of the onset of
symptoms.
Class II
This category applies to patients who
1. are within 6 to 12 hours of the onset of an acute
myocardial infarction and have no symptoms of myocar-
dial ischemia but have a large area of myocardium at
jeopardy and/or are in a higher-risk clinical category
2. are within 12 to 24 hours of the onset of an acute
myocardial infarction but who have continued symp-
toms of ongoing myocardial ischemia, or
3. have received thrombolytic therapy and have con-
tinuing or recurrent symptoms of active myocardial
ischemia.
Class III
This category applies to
1. angioplasty of a non-infarct-related artery at the
time of acute myocardial infarction,
2. patients who are more than 12 hours after the onset
of acute myocardial infarction at the time of admission
and who have no symptoms of myocardial ischemia, or
3. patients who have had successful thrombolytic
therapy within the past 24 hours and have no symptoms
of myocardial ischemia.
The role of direct angioplasty in the management of
patients during the course of acute myocardial infarc-
tion is currently the subject of intense investigation.142
Two major factors leading to the current interest in
"primary" angioplasty in acute myocardial infarction
patients without preceding fibrinolytic therapy are (1)
the realization that <25% of acute myocardial infarc-
tion patients in the United States receive fibrinolytic
therapy and (2) the findings of three large clinical trials
that bleeding complications were seen more frequently
when PTCA was preceded by intravenous thrombolytic
therapy with tissue plasminogen activator.143-145 Not
only were transfusion rates after immediate angioplasty
two to three times those reported after deferred angio-
plasty, overall mortality and left ventricular function
were not significantly improved by the combination
strategy.146 A number of single-center, nonrandomized,
noncontrolled studies indicate that the procedure is
effective as a primary means of establishing reperfusion
in the early hours of an evolving myocardial infarc-
tion.147-15' The procedure is associated with the relief of
acute symptoms and associated with acceptable mortal-
ity rates when dilation has been successful.
In addition, there are observational data from one
large registry study152 and several randomized clinical
trials'53-'56 comparing direct angioplasty with intrave-
nous thrombolytic therapy in patients with acute myo-
cardial infarction. These data suggest that direct PTCA
is at least as efficacious as thrombolytic therapy and, in
certain subsets of patients, may even be superior in
terms of recurrent ischemic events, cost reduction, and
short-term survival. Although these observations have
major implications for the large cohort of acute myo-
cardial infarction patients who are ineligible for throm-
bolytic therapy, there are substantial differences in
terms of mortality risk between a population of acute
myocardial infarction patients who are eligible and
those who are ineligible for thrombolytic therapy.157
Although it may appear that direct angioplasty may be
the desirable therapeutic approach for patients ineligi-
ble for thrombolysis, it seems wise to test this hypothesis
in well-designed, prospective, randomized clinical tri-
als,142 particularly in light of the unexpected findings of
the randomized trials of the potential benefits of follow-
ing thrombolytic therapy with immediate PTCA.143-'45
One group of patients who appear to achieve signif-
icant benefit from direct PTCA, particularly when it is
done in conjunction with the use of the intra-aortic
balloon pump for hemodynamic support, is that com-
prising patients with cardiogenic shock complicating
acute myocardial infarction.72'73"58"59 Compared with
the conventionally high mortality associated with car-
diogenic shock (approximately 80%), a relatively low
in-hospital mortality (approximately 40%) has been
observed in selected patients with cardiogenic shock
treated with successful angioplasty.159-'63 Angioplasty
may, thus, offer some benefit for patients who experi-
ence cardiogenic shock complicating acute myocardial
infarction, particularly those who are within 12 hours of
symptom onset.'64
After Acute Myocardial Infarction (Angioplasty
During Initial Hospitalization)
Class I
This category applies to the dilation of any significant
lesion(s) in patients who
1. have recurrent episodes of ischemic chest pain,
particularly if accompanied by electrocardiographic
changes (postinfarction angina), or
2. show objective evidence of myocardial ischemia
during laboratory testing performed before discharge
from the hospital, or
3. have recurrent sustained ventricular tachycardia or
ventricular fibrillation, or both, while receiving intensive
medical therapy.
All of these patients should have one or more lesions
that predict a high (>90%) success rate and be at low
risk for morbidity and mortality.
Class II
This category applies to the dilation of significant
lesions in patients who
1. are similar to patients in Class I but
a. have more complex lesions with at least a moderate
likelihood of successful dilation, or
b. undergo multivessel angioplasty, or
c. are at moderate risk for morbidity or mortality or
both, or
2. have survived cardiogenic shock in the period
before discharge or
3. are asymptomatic but have a significant residual
lesion in the infarct-related artery supplying a large or
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moderate area of angiographically functioning myocar-
dium, or
4. have had a non-Q-wave myocardial infarction, and
a. have a large area at risk or objective evidence of
myocardial ischemia, and
b. single-vessel disease with noncomplex lesion mor-
phology, and
c. are at low risk for morbidity and mortality.
Class III
This category applies to all other patients in the
immediate postinfarction period (during initial hospital-
ization) who do not fulfill the preceding criteria for
Class I and Class II. It includes, for example,
1. dilation of borderline residual lesions (50% to 60%
diameter reduction) in the absence of spontaneous or
stress-induced ischemia, or
2. dilation of chronic total occlusions subtending
nonviable myocardium, or
3. angioplasty in patients at high risk for morbidity
and mortality.
The selection of patients for coronary angiography
and subsequent revascularization procedures in the
recovery phase following acute myocardial infarction
continues to be a subject of vital importance for ongoing
study. Although the indications for PTCA in a non-
infarct-related artery are similar to those outlined in the
introduction and "General Considerations" for all pa-
tients undergoing coronary angioplasty, controversy
continues about the proper approach to the infarct-
related artery in this setting.
The use of angioplasty in conjunction with thrombo-
lytic therapy has been one of the most intensely studied
issues to date. Data from a number of important ran-
domized clinical trials all suggest that angioplasty should
be deferred and performed as clinically indicated follow-
ing successful thrombolysis.143-146 Studies have also
shown that angioplasty can be performed successfully in
the majority of patients in whom recanalization fails
following thrombolytic therapy alone.165-167 The likeli-
hood of successful dilation in this situation ("salvage
PTCA") may also be influenced by the type of fibrinolytic
agent previously administered.168,169 Although successful
mechanical recanalization of patients who fail thrombol-
ysis appears to be associated with a low hospital mortality
rate similar to that observed after successful thromboly-
sis, it is critical to recognize the high mortality rates
reported in patients after failed attempts at either direct
or salvage PTCA.169,170 These rates range between 30%
and 40% and underscore the importance of caution in
the use of angioplasty in acute infarction patients.
Ongoing analyses of patient subgroups in completed
trials continue to generate new observations that chal-
lenge existing hypotheses and raise questions with far-
reaching clinical implications. An example is the issue
and uncertainty surrounding the value of an open
infarct-related artery at the time of discharge from the
hospital after infarction in the absence of demonstrated
myocardial ischemia.171 173 Similarly, data are now
emerging to suggest that angioplasty of significant re-
sidual lesions in infarct-related arteries in some subsets
of patients without symptoms but with objective evi-
dence of ischemia after thrombolytic therapy may be
harmful.174 It should be apparent that such subset
analyses produce exploratory results that provide clear
direction for new lines of investigation but certainly do
not establish firm guidelines for clinical practice.
It is in this context that these guidelines are promul-
gated, with the conviction that the prudent physician
will have no difficulty in identifying those areas about
which firm clinical opinion is established and those that
represent new frontiers of practice that must await
confirmation from additional clinical investigation.
Appendix A
This classification is adopted from the grading of angina of
effort by the Canadian Cardiovascular Society.175
I. Angina is not caused by ordinary physical activity, such as
walking and climbing stairs. Angina is experienced with stren-
uous or rapid or prolonged exertion at work or recreation.
II. There is slight limitation of ordinary activity, such as
walking or climbing stairs rapidly; walking uphill; walking or
stair-climbing after meals; or walking more than two blocks on
the level or climbing more than one flight of ordinary stairs at
a normal pace and in normal conditions; or angina is experi-
enced in cold, in wind, during emotional stress, or only during
the few hours after awakening.
III. There is marked limitation of ordinary physical activity,
such as walking one to two blocks on the level or climbing one
flight of stairs in normal conditions and at a normal pace.
IV. There is an inability to carry on any physical activity
without discomfort; anginal syndrome may be present at rest.
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